Global Antibody Drugs Market: Overview
Antibodies are large Y-shaped proteins, which help immune system to identify and neutralize foreign objects such as bacteria and viruses in the human body. Gaining from the advancements in the field of biotechnology in the past two decades since the first antibody drug was made commercially available in 1986, several antibody drugs are now available. This drugs not only have fewer side effects as compared to other alternatives, they attain high efficacy too in curing certain diseases that were previously considered untreatable. Due to this undeniable benefit and immense possibilities in future, the global market for antibody drugs is gaining quick momentum and investors are currently investing aggressively in the research and development of new antibody drugs. By 2009, nearly 30 new antibody drugs were available in the market for consumers and according to the report, the global market for antibody drugs will expand at a healthy CAGR during the forecast period of 2016 to 2024.
Global Antibody Drugs Market: Trends and Opportunities
There are a number products in the late-pipeline stage of clinical trials, which are expected to be introduced during the forecast period and in turn will drive the growth prospects of the global market for antibody drugs. For example, products such as glembatumumab vedotin by Seattle Genetics and trastuzumab by Synthon Biopharmaceuticals are due to be launched in the next five years. Additionally, some molecules are in Phase I/II, preclinical, and discovery stages. Another factor augmenting the demand for antibody drugs is the fewer side effects, which is attracting more physicians to prescribe it and consumers to opt for it. Additionally, the emergence of targeted and combination therapies will positively affect this market over the coming years. Targeted therapies have fewer adverse effects than conventional non-targeted therapies because they utilize the surface markers of infected cells, which are absent or are in lower amounts in normal cells.
Researchers are yet to find effective drugs to cure highly prevalent diseases such as cancer, nervous system ailments, and allergic diseases, but with advancements in antibody drug conjugates (ADC), possibilities are enormous. This progress is another driving factor for the market. However, high cost of these drugs and some of the side effects are expected to hinder the growth rate during the forecast period.
The global market for antibody drugs can be segmented on the basis of end users, application, and type of drugs, and geography. By end users, the market is segmented into hospitals, long-term care facilities, and research institutes. Currently, hospitals serve the maximum demand. By drug type, the market can be segmented into monoclonal antibodies, antibody-drug conjugates, and polyclonal antibodies. Presently, monoclonal antibodies account for the maximum market share, and is expected to expand at the most significant CAGR during the forecast period. By disease application, the market can be segmented into central nervous system (CNS) disorders, cancer and autoimmune disorders, and cardiovascular diseases. The cancer indication type segment accounted for the most prominent share in 2015.
Global Antibody Drugs Market: Region-wise Outlook
Geographically, the market can be segmented into North America, Latin America, Western Europe, Eastern Europe, Asia Pacific, and Rest of the World. Presently, North America accounts for the maximum market share due to factors such as robust healthcare infrastructure, necessity of addressing urgent unmet need in treatment of cancer and immunological diseases such as rheumatoid, greater affordability of the consumers, and high rate of adoptability of new technology. North America market is expected to retain its position on top of the market, however, Asia Pacific is projected for a fastest growth rate due to improving healthcare sector in the region and vast patient base.
Companies mentioned in the research report
Novartis AG, Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., AbbVie Inc., and Eli Lilly and Co. are identified as some of the prominent names in the global market for antibody drugs. In 2015, F. Hoffmann-La Roche Ltd. was the global leader, dominating with a wide product portfolio, including monoclonal antibodies, bispecific antibodies, antibodies fusion proteins, and antibody drug conjugates. Flagship products of the company include Herceptin, Rituxan, Avastin, and Lucentis. The report also notes that several players are focused on co-marketing and co-development products, which will enhance their presence in the market. Additionally, collaborations and partnerships also enable these companies to increase visibility of their products.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.